The tight Relationship between Osteoclasts and the Immune System

Inflammation and Allergy - Drug Targets

Volumn 11, Issue 3, 2012, Pages 181-187

  del Fattore, Andrea ^a   Teti, Anna ^b  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

B cells; Bone; Immune system; Osteoclast; Osteoimmunology; Rankl; T cells

Indexed keywords

B7 ANTIGEN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE IV; CD40 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; CYTOKINE; FC RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; KILLER CELL ACTIVATING RECEPTOR ASSOCIATED PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PROTEIN SH2; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TRANSCRIPTION FACTOR PAX5; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ALBERS SCHOENBERG DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; BONE MATRIX; BONE METABOLISM; CELL DIFFERENTIATION; CYTOKINE PRODUCTION; GIANT CELL; HEMATOPOIETIC CELL; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INFLAMMATORY DISEASE; INNATE IMMUNITY; LYMPHOCYTE DIFFERENTIATION; LYMPHOPOIESIS; MACROPHAGE; MONOCYTE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; SKELETON; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL;

EID: 84860465167     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152812800392733     Document Type: Article

References (96)

1. th Ed., 2009, pp. 16-22.
2. Fukumoto, S.; Martin, T.J. Bone as an endocrine organ. TrendsEndocrinol. Metab., 2009, 20, 230-236.
3. Confavreux, C.B.; Levine, R.L.; Karsenty, G. A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms. Mol. Cell Endocrinol., 2009, 310, 21-29.
4. Yadav, V.K.; Oury, F.; Suda, N.; Liu, Z.W.; Gao, X.B.; Confavreux, C.; Klemenhagen, K.C.; Tanaka, K.F.; Gingrich, J.A.; Guo, X.E.; Tecott, L.H.; Mann, J.J.; Hen, R.; Horvath, T.L.; Karsenty, G. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell, 2009, 138, 976-989.
5. Ferron, M.; Wei, J.; Yoshizawa, T.; Del Fattore, A.; DePinho, R.A.; Teti, A.; Ducy, P.; Karsenty G. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell, 2010, 142, 296-308.
6. Fulzele, K.; Riddle, R.C.; Di Girolamo, D.J.; Cao, X.; Wan, C.; Chen, D.; Faugere, M.C.; Aja, S.; Hussain, M.A.; Brüning, J.C.; Clemens, T.L. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell, 2010, 142, 309-319.
7. Oury, F.; Sumara, G.; Sumara, O.; Ferron, M.; Chang, H.; Smith, C.E.; Hermo, L.; Suarez, S.; Roth, B.L.; Ducy, P.; Karsenty, G. Endocrine regulation of male fertility by the skeleton. Cell, 2011,142, 796-809.
8. Garrett, R.W.; Emerson, S.G. Bone and blood vessels: the hard and the soft of hematopoietic stem cell niches. Stem Cell, 2009, 4, 503-506.
9. Rosemberg, H.F.; Gallin, J.I.; Paul, W.E. In Inflammation; Paul WE, Ed.; Fundamental Immunology: Philadelphia, 1999; 1051.
10. Walker, D.G. Bone resorption restored in osteopetrotic mice by transplants of normal bone marrow and spleen cells. 1975. Clin. Orthop. Relat. Res., 1993, 294, 4-6.
11. Walker, D.G. The classic: Osteopetrosis cured by temporary parabiosis. Clin. Orthop. Relat. Res., 1982, 162, 2-3.
12. Horton, J.E.; Raisz, L.G.; Simmons, H.A.; Oppenheim, J.J.; Mergenhagen, S.E. Bone resorbing activity in supernatant fluid from cultured human peripheral blood leukocytes. Science, 1972, 177, 793-795.
13. Mundy, G.R.; Raisz, L.G.; Cooper, R.A; Schechter, G.P.; Salmon, S.E. Evidence for the secretion of an osteoclast stimulating factor in myeloma. N. Engl. J. Med., 1974, 291, 1041-1046.
14. Dewhirst, F.E.; Stashenko, P.P.; Mole, J.E.; Tsurumachi, T. Purification and partial sequence of human osteoclast-activating factor: identity with interleukin 1. J. Immunol, 1985, 135, 2562-2568.
15. H. New immune connections in osteoclast formation. Ann. N.Y. Acad. Sci., 2010, 1192, 117-123.
16. Alnaeeli, M.; Penninger, J.M.; Teng, Y.T. Immune interactions with CD41 T cells promote the development of functional osteoclasts from murine CD11c1 dendritic cells. J. Immunol, 2006, 177, 3314-3326.
17. Lorenzo, J.; Horowitz, M.; Choi, Y. Osteoimmunology: interactions of the bone and immune system. Endocrine Reviews, 2008, 29, 403-440.
18. Lee, S.H.; Kim, T.S.; Choi, Y.; Lorenzo, J. Osteoimmunology: cytokines and the skeletal system. BMB Rep., 2008, 41, 495-510.
19. McLean, R.R. Proinflammatory cytokines and osteoporosis. Curr. Osteoporos. Rep., 2009, 7, 134-139.
20. Mensah, K.A; Li, J.; Scwarz, E.M. The emerging field of osteoimmunology. Immunol Res., 2009, 45, 100-113
21. Schett, G. Osteoimunology in rheumatic diseases. Arthritis Res Ther., 2009, 11, 210.
22. O'Gradaigh, D.; Compston, J.E. T-cell involvement in osteoclast biology: implications for rheumatoid bone erosion. Rheumatology, 2004, 43, 122-130.
23. Arron, J.R.; Choi, Y. Bone versus immune system. Nature, 2000, 408, 535-536.
24. Takayanagi, H.; Ogasawara, K.; Hida, S.; Chiba, T.; Murata, S.; Sato, K.; Akinori, T.; Yokochi, T.; Oda, H.; Tanaka, K.; Nakamura, K.; Taniguchi, T. T cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-y. Nature, 2000, 408, 600-605.
25. Takayanagi, H. Mechanistic insight into osteoclast differentiation in osteoimmunology. J. Mol. Med., 2005, 83, 170-179.
26. Ghia, P.; ten Boekel, E.; Rolink, A.G.; Melchers, F. B-cell development: a comparison between mouse and man. Immunol. Today, 1998, 19, 480-485.
27. Grcevic, D.; Katavic, V.; Lukic, I.K.; Kovacic, N.; Lorenzo, J.A.; Marusic, A. Cellular and molecular interactions between immune system and bone. Croat. Med. J., 2001, 42, 384-392.
28. Miyake, K.; Medina, K.; Ishihara, K.; Kimoto, M.; Auerbach, R.; Kincade, P.W. A VCAM-like adhesion molecule on murine bone marrow stromal cells mediates binding of lymphocyte precursors in culture. J. Cell Biol, 1991, 114, 557-565.
29. Koni, P.A.; Joshi, S.K.; Temann, U.A. Conditional vascular cell adhesion molecule 1 deletion in mice: Impaired lymphocyte migration to bone marrow. J. Exp. Med., 2001, 193, 741-753.
30. Lawson, C; Ainsworth, M.; Yacoub, M.; Rose, M. Ligation of ICAM-1 on endothelial cells leads to expression of VCAM-1 via a nuclear factor-kB-independent mechanism. J. Immunol, 1999, 5, 2990-2996.
31. Kong, Y.Y.; Yoshida, H.; Sarosi, I.; Tan, H.L.; Timms, E.; Capparelli, C; Morony, S.; Oliveira-dos-Santos, A.J.; Van, G.; Itie, A.; Khoo, W.; Wakeham, A.; Dunstan, C.R.; Lacey, D.L.; Mak, T.W.; Boyle, W.J.; Penninger, J.M. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature, 1999, 397, 315-323.
32. Sobacchi, C; Frattini, A.; Guerrini, M.M.; Abinun, M.; Pangrazio, A.; Susani, L.; Bredius, R.; Mancini, G.; Cant, A.; Bishop, N.; Grabowski, P.; Del Fattore, A.; Messina, C; Errigo, G.; Coxon, F.P.; Scott, D.I.; Teti, A.; Rogers, M.J.; Vezzoni, P.; Villa, A.; Helfrich, M.H. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat. Genet, 2007, 39, 960-962.
33. Guerrini, M.M.; Sobacchi, C; Cassani, B.; Abinun, M.; Kilic, S.S.; Pangrazio, A.; Moratto, D.; Mazzolari, E.; Clayton-Smith, J.; Orchard, P.; Coxon, F.P.; Helfrich, M.H.; Crockett, J.C.; Mellis, D.; Vellodi, A.; Tezcan, I.; Notarangelo, L.D.; Rogers, M.J.; Vezzoni, P.; Villa, A.; Frattini, A. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am. J. Hum. Genet, 2008, 83, 64-76.
34. Horowitz, M.C.; Fretz, J.A.; Lorenzo, J.A. How B cells influence bone biology in health and disease. Bone, 2010, 47(3), 472-479.
35. Yun, T.J.; Tallquist, M.D.; Aicher, A.; Rafferty, K.L.; Marshall, A.J.; Moon, J.J.; Ewings, M.E.; Mohaupt, M.; Herring, S.W.; Clark, E.A. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J. Immunol, 2001, 166, 1482-1491.
36. Li, Y.; Toraldo, G.; Li, A.; Yang, X.; Zhang, H.; Qian, W.P.; Weitzmann, M.N. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood, 2007, 109, 3839-3848.
37. Pacifici, R. The immune system and bone. Arch. Biochem. Biophys., 2010, 503, 41-53.
38. Scott, E.; Simon, M.C.; Anastasi, J.; Singh, H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science, 1994, 265, 1573-1677.
39. McKercher, S.R.; Torbett, B.E.; Anderson, K.L.; Henkel, G.W.; Vestal, D.J.; Baribault, H.; Klemsz, M.; Feeney, A.J.; Wu, G.E.; Paige, C.J.; Maki, R.A. Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO J., 1996, 15, 5647-5658.
40. DeKoter, R.; Lee, H.J.; Singh, H. PU.1 regulates expression of the interleukin-7 receptor in lymphoid progenitors. Immunity, 2002, 16, 297-309.
41. DeKoter, R.; Singh, H. Regulation of B lymphocytes and macrophage development by graded expression of PU.1. Science, 2000,288, 1439-1441.
42. Manabe, N.; Kawaguchi, H.; Chikuda, H.; Miyaura, C; Inada, M.; Nagai, R.; Nabeshima, Y.; Nakamura, K.; Sinclair, A.M.; Scheuermann, R.H.; Kuro-o, M. Connection between B lymphocyte and osteoclast differentiation pathways. J. Immunol, 2001, 167, 2625-2631.
43. Katavic, V.; Grcevic, D.; Lee, S.K.; Kalinowski, J.; Jastrzebski, S.; Dougall, W.; Anderson, D.; Puddington, L.; Aguila, H.L.; Lorenzo, J.A. The surface antigen CD45R identifies a population of estrogen-regulated murine marrow cells that contain osteoclast precursors. Bone, 2003, 32, 581-590.
44. Sato, T.; Shibata, T.; Ikeda, K.; Watanabe, K. Generation of bone resorbing osteoclasts from B220+ cells: its role in accelerated osteoclastogenesis due to estrogen deficiency. J. Bone Miner. Res., 2001, 16, 2215-2221.
45. Bataille, R.; Harousseau, J.L. Multiple myeloma. N. Engl. J. Med., 1997, 336, 1657-1664.
46. Oyajobi, B.O.; Mundy GR. In: Gahrton G, Durie BGM, Samson DM, Eds. Multiple Myeloma and Related Disorders. Pathophysiology of myeloma bone disease. London: Arnold, 2004, pp. 74-88.
47. Silvestris, F.; Ciavarella, S.; De Matteo, M.; Tucci, M.; Dammacco, F. Bone-resorbing cells in multiple myeloma: osteoclasts, myeloma cell polykaryons, or both? Oncologist, 2009, 14, 264-275.
48. th ed. W.B. Saunders company. St. Louis, 2000.
49. Godfrey, D.I.; MacDonald, H.R.; Kronenberg, M.; Smyth, M.J.; Van Kaer, L. NKT cells: what's in a name?. Nat. Rev. Immunol, 2004, 4, 231-237.
50. Lee, S.K., Lorenzo, J. Cytokines regulating osteoclast formation and function. Curr. Opin. Rheumatol. 2006, 1, 4811-4818.
51. Fox, S.W.; Chambers, T.J. Interferon-gamma directly inhibits TRANCE-induced osteoclastogenesis. Biochem. Biophys. Res. Commun., 2000, 276, 868-872.
52. Gao, Y.; Grassi, F.; Ryan, M.R.; Terauchi, M.; Page, K.; Yang, X.; Weitzmann, M.N.; Pacifici, R IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J. Clin. Invest, 2007, 117, 122-132.
53. Hanada, R.; Hanada, T.; Penninger, J.M. Physiology and pathophysiology of the RANKL/RANK system. Biol. Chem., 2010, 391, 1365-1370.
54. Harrington, L.E.; Hatton, R.D.; Mangan, P.R; Turner, H.; Murphy, T.L.; Murphy, K.M.; Weaver, C.T. Interleukin 17-producing CD4? Effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol, 2005, 6, 1123-1132.
55. Lubberts, E. The role of IL-17 and family members in the pathogenesis of arthritis. Curr. Opin. Investig. Drugs, 2003, 4, 572-577.
56. Bush, K.A; Farmer, K.M.; Walker, J.S.; Kirkham, B.W. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum., 2002, 46, 802-805.
57. Lubberts, E.; Koenders, M.I.; Oppers-Walgreen, B.; van den Bersselaar, L.; Coenen-de Roo, C.J.; Joosten, L.A., van de Berg, W.B. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum., 2004, 50, 650-659.
58. Sato, K.; Suematsu, A.; Okamoto, K.; Yamaguchi, A.; Morishita, Y.; Kadono, Y.; Tanaka, S., Kodama, T.; Akira, S.; Iwakura, Y.; Cua, D.J.; Takayanagi H. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med., 2006,203, 2673-2682.
59. Li, Y.; Toraldo, G.; Li, A.; Yang, X.; Zhang, H.; Qian, W.P.; Weitzmann, M.N. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood, 2007,109, 3839-3848.
60. Volpe, E.; Servant, N.; Zollinger, R.; Bogiatz i, S.I.; Hupe, P.; Ba rillot, E.; Soumelis, V. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat. Immunol., 2008, 9, 650-657.
61. R. T cells: Critical bone regulators in health and disease. Bone, 2010, 47(3), 461-471.
62. Roggia, C.; Gao, Y.; Cenci, S.; Weitzmann, M.N.; Toraldo, G.; Isaia, G.; Pacific, R. Up-regulation of TNF-producing T cells in the bone marrow: A key mechanism by which estrogen deficiency induces bone loss in vivo. Proc. Natl. Acad. Sci. U S A, 2001, 98, 13960-13965.
63. Cenci, S.; Weitzmann, M.N.; Roggia, C.; Namba, N.; Novack, D.; Woodring, J.; Pacifici, R. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J. Clin. Invest., 2000, 106, 1229-1237.
64. Gao, Y.; Qian, W.P.; Dark, K.; Toraldo, G.; Lin, A.S.; Guldberg, R.E.; Flavell, R.A.; Weitzmann, M.N.; Pacifici, R. Estrogen prevents bone loss through transforming growth factor beta signaling in T cells. Proc. Natl. Acad. Sci. U S A, 2004, 101, 16618-16623.
65. Grassi, F.; Tell, G.; Robbie-Ryan, M.; Gao, Y.; Terauchi, M.; Yang, X.; Romanello, M.; Jones, D.P.; Weitzmann, M.N.; Pacifici, R. Oxidative stress causes bone loss in estrogen-deficient mice through enhanced bone marrow dendritic cell activation. Proc. Natl. Acad. Sci. U S A, 2007, 104, 15087-15092.
66. Yamaza, T.; Miura, Y.; Bi, Y.; Liu, Y.; Akiyama, K.; Sonoyama, W.; Patel, V.; Gutkind, S.; Young, M.; Gronthos, S.; Le, A.; Wang, C.Y.; Chen, W.; Shi, S. Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. PLoS ONE, 2008, 3, e2615.
67. D'Amelio, P.; Grimaldi, A.; Di Bella, S.; Brianza, S.Z.; Cristofaro, M.A.; Tamone, C.; Tamone, C.; Giribaldi, G.; Ulliers, D.; Pescarmona, G.P.; Isaia, G. Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. Bone, 2008, 43, 92-100.
68. Gao, Y.; Wu, X.; Terauchi, M.; Li, J.Y.; Grassi, F.; Galley, S.; Yang, X.; Weitzmann, M.N.; Pacifici, R. T cells potentiate PTH-induced cortical bone loss through CD40L signaling. Cell Metab., 2008, 8, 132-145.
69. Grey, A.B.; Stapleton, J.P.; Evans, M.C.; Reid, I.R. Accelerated bone loss in post-menopausal women with mild primary hyperparathyroidism. Clin. Endocrinol. (Oxf)., 1996, 44, 697-702.
70. Parisien, M.; Dempster, D.W.; Shane, E.; Bilezikian, J.P. The parathyroids. Basic and clinical concepts. San Diego: Academic Press;. Histomorphometric analysis of bone in primary hyperparathyroidism; 2001; pp. 423-436.
71. Potts, J. Primary hyperparathyroidism. In: Krane LVAaS., editor. Metabolic Bone Diseases. San Diego: Academic Press; 1998. pp. 411-442.
72. Silverberg, S.J.; Shane, E.; de la Cruz, L.; Dempster, D.W.; Feldman, F.; Seldin, D.; Jacobs, T.P.; Siris, E.S.; Cafferty, M.; Parisien, M.V., Lindsay, R.; Clemens, T.L.; Bilezikian, J.P. Skeletal disease in primary hyperparathyroidism. J. Bone Miner. Res., 1989, 4, 283-291.
73. Qin, L.; Raggatt, L.J.; Partridge, N.C.; Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol. Metab., 2004, 15, 60-65.
74. Riggs, B.L.; Melton, L.J. Involutional osteoporosis. N. Engl. J. Med., 1986, 314, 1676-1686.
75. Canalis, E.; Giustina, A.; Bilezikian, J.P. Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med., 2007, 357, 905-916.
76. Di Rosa, F.; Pabst, R. The bone marrow: a nest for migratory memory T cells. Trends Immunol., 2005, 26, 360-366.
77. Ahuja, S.S.; Zhao, S.; Bellido, T.; Plotkin, L.I.; Jimenez, F.; Bonewald, L.F. CD40 ligand blocks apoptosis induced by tumor necrosis factor alpha, glucocorticoids, and etoposide in osteoblasts and the osteocyte-like cell line murine long bone osteocyte-Y4. Endocrinology, 2003, 144, 1761-1769.
78. Pettway, G.J.; Schneider, A.; Koh, A.J.; Widjaja, E.; Morris, M.D.; Meganck, J.A.; Goldstein, S.A.; McCauley, L.K. Anabolic actions of PTH (1-34): use of a novel tissue engineering model to investigate temporal effects on bone. Bone, 2005, 36, 959-970.
79. Terauchi, M.; Li, J.Y.; Bedi, B.; Baek, K.H.; Tawfeek, H.; Galley, S.; Gilbert, L.; Nanes, M.S.; Zayzafoon, M.; Guldberg, R.; Lamar, D.L.; Singer, M.A.; Lane, T.F.; Kronenberg, H.M.; Weitzmann, M.N.; Pacifici, R. T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling. Cell Metab., 2009, 10, 229-240.
80. Negishi-Koga, T.; Takayanagi, H. Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation. Immunol. Rev., 2009, 231, 241-256.
81. Hamerman, J.A.; Ni, M.; Killebrew, J.R.; Chu, C.L.; Lowell, C.A. The expanding roles of ITAM adapters FcRgamma and DAP12 in myeloid cells. Immunol. Rev., 2009, 232, 42-58.
82. Koga, T.; Inui, M.; Inoue, K.; Kim, S.; Suematsu, A.; Kobayashi, E.; Iwata, T.; Ohnishi, H.; Matozaki, T.; Kodama, T.; Taniguchi, T.; Takayanagi, H.; Takai T. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature, 2004, 428, 758-763.
83. Takayanagi, H. Mechanistic insight into osteoclast differentiation in osteoimmunology. J. Mol. Med., 2005, 83, 170-179.
84. Nishikawa, K.; Nakashima, T.; Hayashi, M.; Fukunaga, T.; Kato, S.; Kodama, T.; Takahashi, S.; Calame, K.; Takayanagi, H. Blimp1-mediated repression of negative regulators is required for osteoclast differentiation. Proc. Natl. Acad. Sci. USA, 2010, 107, 3117-3122.
85. Martins, G.; Calame, K. Regulation and functions of Blimp-1 in T and B lymphocytes. Annu. Rev. Immunol., 2008, 26, 133-169.
86. Zhao, B.; Takami, M.; Yamada, A.; Wang, X.; Koga, T.; Hu, X.; Tamura, T.; Ozato, K.; Choi, Y.; Ivashkiv, L.B.; Takayanagi, H.; Kamijo, R. Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nat. Med., 2009, 15, 1066-1071.
87. Kim, K.; Kim, J.H.; Lee, J.; Jin, H.M.; Kook, H.; Kim, K.K.; Lee, S.Y.; Kim, N. MafB negatively regulates RANKL-mediated osteoclast differentiation. Blood, 2007, 109, 3253-3259.
88. Li, H.; Hong, S.; Qian, J.; Zheng, Y.; Yang, J.; Yi, Q. Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells. Blood, 2010, 116, 210-217.
89. Baron, R. Arming the osteoclast. Nat. Med., 2004, 10, 458-460.
90. Del Fattore, A.; Teti, A.; Rucci, N. Osteoclast receptors and signaling. Arch Biochem Biophys., 2008, 473, 147-160.
91. Teti, A.; Rucci, N. The unexpected links between bone and the immune system. Medicographia, 2010, 32, 341-348.
92. Gowen, M.; MacDonald, B.R.; Hughes, D.E.; Skjodt, H.; Russell, R.G. Immune cells and bone resorption. Adv. Exp. Med. Biol., 1986, 208, 261-273
93. Horton, M.A.; Rimmer, E.F.; Lewis, D.; Pringle, J.A.; Fuller, K.; Chambers, T.J. Cell surface characterization of the human osteoclast: phenotypic relationship to other bone marrow-derived cell types. J. Pathol., 1984, 144, 281-294.
94. Xing, L.; Schwarz, E.M.; Boyce, B.F. Osteoclast precursors, RANKL/RANK, and immunology. Immunol. Rev., 2005, 208, 19-29.
95. Takayanagi, H. The role of NFAT in osteoclast formation. Ann. N.Y. Acad. Sci. USA, 2007, 1116, 227-237.
96. Chambers, T.J.; Darby, J.A.; Fuller, K. Mammalian collagenase predisposes bone surfaces to osteoclastic resorption. Cell Tissue Res., 1985, 241, 671-675.